grant
Towards characterization of Epigenetic targets in Prostate Cancer
Organization UNIVERSITY OF PENNSYLVANIALocation PHILADELPHIA, UNITED STATESPosted 1 Mar 2025Deadline 28 Feb 2030
NIHUS FederalResearch GrantFY2025AffectAmerican maleAmerican manAmerican menAndrogen ReceptorAndrogenic AgentsAndrogenic CompoundsAndrogensAnti-androgen TherapyAnti-androgen TreatmentAntibodiesApplications GrantsAssayAutomobile DrivingBasal Transcription FactorBasal transcription factor genesBindingBioassayBiochemicalBiological AssayBiological FunctionBiological ProcessCRISPRCRISPR editing screenCRISPR screenCRISPR-based screenCRISPR/Cas systemCRISPR/Cas9 screenCancer CauseCancer Cell GrowthCancer EtiologyCancer PatientCancersCell BodyCell Communication and SignalingCell SignalingCellsCessation of lifeChIP SequencingChIP-seqChIPseqChromatinChromatin LoopChromatin Loop DomainsClinical TrialsClustered Regularly Interspaced Short Palindromic RepeatsComplexDNA LoopDNA mutationDataDeathDependenceDevelopmentDiseaseDisorderDrug IndustryDrug resistanceEMSAENX-1EZH1EZH2EZH2 geneEarly-Stage Clinical TrialsEnhancer ElementsEnhancer of Zeste 2 Polycomb Repressive Complex 2 SubunitEnhancersEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEpithelial CellsEpitheliumGene Action RegulationGene Expression RegulationGene RegulationGene Regulation ProcessGene TranscriptionGeneral Transcription Factor GeneGeneral Transcription FactorsGeneralized GrowthGenetic ChangeGenetic Enhancer ElementGenetic TranscriptionGenetic defectGenetic mutationGoalsGrant ProposalsGrowthHMG-1 DomainHMG-1-Box DomainHMG-BoxHMG-Box DomainsHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoietic CancerHeterograftHeterologous TransplantationHigh Mobility Group-Box DomainsHistone-Lysine MethyltransferaseHistone-Lysine N-MethyltransferaseHistonesHyperactivityIn VitroIntracellular Communication and SignalingKMT6KMT6AKnock-inKnowledgeLigandsLuciferase ImmunologicLuciferasesLytotoxicityMMSET GeneMacromolecular StructureMalignantMalignant - descriptorMalignant CellMalignant Hematologic NeoplasmMalignant NeoplasmsMalignant TumorMalignant neoplasm of prostateMalignant prostatic tumorMediatingMetastatic Prostate CancerMethylationModelingModificationMolecularMolecular InteractionMolecular StructureMultiple MyelomaMutationNSD2 GeneNamesNucleosomesOncogenicOperative ProceduresOperative Surgical ProceduresOrganoidsOutcomePDX modelPathogenesisPatient derived xenograftPatientsPharmaceutic IndustryPharmaceutical IndustryPhase 1 Clinical TrialsPhase I Clinical TrialsPhenotypePlasma-Cell MyelomaPlayProstateProstate CAProstate CA therapyProstate CancerProstate Cancer therapyProstate Carcinoma MetastaticProstate GlandProstate NeoplasmsProstate TumorProstate malignancyProstaticProstatic GlandProstatic NeoplasiaProstatic NeoplasmsProtein Lysine MethyltransferaseProtein Methylase IIIProtein Methyltransferase IIIProteinsProteomicsRNA ExpressionRNA SeqRNA sequencingRNAseqRadiationReceptor SignalingRefractoryReporterResistance developmentResistant developmentRoleSET DomainSignal TransductionSignal Transduction SystemsSignalingSingle Crystal DiffractionSiteSite-Directed MutagenesisSite-Specific MutagenesisSurgicalSurgical InterventionsSurgical ProcedureTRX5 GeneTargeted DNA ModificationTargeted ModificationTestingTherapeuticTherapeutic AndrogenTherapeutically TargetableTimeTissue GrowthTranscriptionTranscription Factor Proto-OncogeneTranscription factor genesU.S. MalesUS MenUS maleWHSC1WHSC1 geneWolf-Hirschhorn Syndrome Candidate 1 GeneWorkX Ray CrystallographiesX-Ray CrystallographyX-Ray Diffraction CrystallographyX-Ray/Neutron CrystallographyXenograftXenograft ModelXenograft procedureXenotransplantationXray CrystallographyXtandiabirateroneadvanced prostate cancerandrogen dependentandrogen independent prostate cancerandrogen indifferent prostate cancerandrogen insensitive prostate cancerandrogen resistance in prostate cancerandrogen resistant prostate cancerandrogen responsiveandrogen sensitiveanti-cancer researchanti-tumor effectantitumor effectbiological signal transductioncancer cellcancer progressioncancer researchcastration resistant CaPcastration resistant PCacastration resistant prostate cancerchromatin immunoprecipitation coupled with sequencingchromatin immunoprecipitation followed by sequencingchromatin immunoprecipitation with sequencingchromatin immunoprecipitation-seqchromatin immunoprecipitation-sequencingchromatin proteinclustered regularly interspaced short palindromic repeats screencofactorcytotoxicitydesigndesigningdetermine efficacydeveloping resistancedevelopmentaldrivingdrug resistantefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationenhancer sequenceenzalutamideepigeneticallyevaluate efficacyexamine efficacyexperimentexperimental researchexperimental studyexperimentsgenetic enhancer sequencegenome mutationgenome scalegenome-widegenomewidehistone methylationhistone modificationhormone refractory prostate cancerin vitro Modelin vivoin vivo Modelinhibitorinsightknockinmales in Americamales in the U.S.males in the USmales in the USAmales in the United Statesmalignancymalignant statemembermenmen in Americamen in the U.S.men in the USmen in the USAmen in the United Statesmultiple myeloma SET domainmutantmyelomamyelomatosisnamenamednamingneoplasm progressionneoplasm/cancerneoplastic progressionnovelontogenyoverexpressoverexpressionparalogparalogous genepatient derived xenograft modelphase I protocolprogramspromoterpromotorprostate cancer cellprostate cancer modelprostate cancer progressionprostate cancer resistant to androgenprostate cancer treatmentprostate tumor cellprostate tumor modelprotein complexrational designreceptor bindingreceptor boundresistance to Drugresistant to Drugresponse to therapyresponse to treatmentsmall molecular inhibitorsmall moleculesmall molecule inhibitorsocial rolesurgerytargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic responsetherapeutic targettherapy responsetranscription factortranscriptome sequencingtranscriptomic sequencingtreatment responsetreatment responsivenesstumortumor growthtumor progressionxeno-transplantxeno-transplantationxenograft transplant modelxenotransplant model
Description preview
Project Summary:
Prostate cancer (PCa) affects nearly 250,000 men in the United States annually, making it the
second leading cause of cancer-related deaths in men, with over 30,000 fatalities each year,
mainly due to metastatic castration-resistant prostate cancer (mCRPC). The androgen receptor
(AR) is a ligand-responsive transcription factor…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click